Kairos Pharma (NYSEAMERICAN:KAPA) Trading Down 0.1% – Here’s Why

Shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) were down 0.1% on Friday . The stock traded as low as $0.6402 and last traded at $0.6644. Approximately 126,041 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 181,725 shares. The stock had previously closed at $0.6648.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Kairos Pharma in a research note on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $8.33.

Kairos Pharma Price Performance

The stock has a market capitalization of $13.83 million, a price-to-earnings ratio of -2.14 and a beta of 2.28. The stock has a 50-day moving average of $0.79 and a 200 day moving average of $1.02.

Kairos Pharma (NYSEAMERICAN:KAPA) last issued its earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Hedge Funds Weigh In On Kairos Pharma

Several institutional investors have recently modified their holdings of KAPA. FNY Investment Advisers LLC bought a new position in Kairos Pharma in the third quarter valued at approximately $27,000. XTX Topco Ltd bought a new stake in shares of Kairos Pharma during the second quarter worth $44,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Kairos Pharma during the third quarter worth $54,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.